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Abstract: The current coronavirus pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in a serious global health crisis. It is a major concern for
individuals living with chronic disorders such as Parkinson’s disease (PD). Increasing evidence
suggests an involvement of oxidative stress and contribution of NFκB in the development of
both COVID-19 and PD. Although, it is early to identify if SARS-CoV-2 led infection enhances
PD complications, it is likely that oxidative stress may exacerbate PD progression in COVID-19
affected individuals and/or vice versa. In the current study, we sought to investigate whether
NFκB-associated inflammatory pathways following oxidative stress in SARS-CoV-2 and PD patients
are correlated. Toward this goal, we have integrated bioinformatics analysis obtained from Basic Local
Alignment Search Tool of Protein Database (BLASTP) search for similarities of SARS-CoV-2 proteins
against human proteome, literature review, and laboratory data obtained in a human cell model of
PD. A Parkinson’s like state was created in 6-hydroxydopamine (6OHDA)-induced differentiated
dopamine-containing neurons (dDCNs) obtained from an immortalized human neural progenitor
cell line derived from the ventral mesencephalon region of the brain (ReNVM). The results indicated
that SARS-CoV-2 infection and 6OHDA-induced toxicity triggered stimulation of caspases-2, -3 and
-8 via the NFκB pathway resulting in the death of dDCNs. Furthermore, specific inhibitors for NFκB
and studied caspases reduced the death of stressed dDCNs. The findings suggest that knowledge
of the selective inhibition of caspases and NFκB activation may contribute to the development of
potential therapeutic approaches for the treatment of COVID-19 and PD.
Keywords: Parkinson’s disease; SARS-CoV-2; caspase; inhibitors; nuclear factor kappa B (NFκB);
6OHDA; oxidative stress; apoptosis
1. Introduction
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) transmitted from human-to-human has impacted almost each and every corner
of the globe and has resulted in a serious health crisis. According to the World Health Organization,
as of September 2020, the rapid viral infection transmission has led to more than 960,000 deaths and
31,000,000 cases globally.
A major proportion of COVID-19 cases suffer from severe acute respiratory distress syndrome
(ARDS), similar to the disease caused by SARS-CoV and MERS-CoV [1,2]. These similarities could
be due to the structural resemblances between the receptor binding domains of SARS-CoV and
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MERS-CoV, as highlighted by recently published studies showing genomic characterization and
epidemiology of SARS-CoV-2 [3,4]. The SARS-CoV-2-induced immunopathogenesis impairs the host
immune system, leading to inflammatory responses. The virus enters the cell through its interaction
with the angiotensin converting enzyme II (ACE2) receptor and transmembrane serine protease-2
(TMPRSS2) [4,5]. Consequently, the level of Angiotensin 2 (AngII) increases in the serum as a result of
its decreased degradation by ACE2. The accumulated AngII has been shown to induce activation of
inflammatory cytokines, including IFN-Y, which is then followed by stimulation of interferon (IFN)
genes, resulting in an enhanced cytokine storm and the related syndrome ARDS, as observed in severe
cases [6–8]. Furthermore, cytokine activation leads to hyperactivation of the down-stream signalling
cascades including the nuclear transcription factor-kappa B (NFκB), which is normally activated by
SARS-CoV-2 itself via pattern recognition receptors (PRRs) [1,7]. Altogether, this comprises a machinery
that acts on the co-activation of signal transducer and activator of transcription 1 and 3 (STAT1 and
STAT3), which further enhances the activation of NFκB [7,9–13], an inducible transcription factor that
has been suggested to trigger apoptotic cell death following oxidative stress and inflammation [14–19].
NFκB resides in the cytoplasm in an inactive form in virtually all cell types. Upon activation,
NFκB enters the nucleus and promotes transcription of different genes such as those encoding caspases,
cytokines, receptors, growth factors, adhesion molecules and chemokines [19,20].
Increased traumatic stress levels seen in SARS-CoV-2 cases may be due to enhanced levels
of inflammatory mediators contributing to clinical complications. This may involve activation of
pulmonary vasculature endothelial cells leading to the development of hypoxia [2,21]. Respiratory
hypoxia seen in COVID-19 patients can also initiate oxidative stress in the brain [22]. It is well known
that hypoxia encourages the production of reactive oxidative species (ROS), which are involved in
inflammation and immune response, thus influencing cell signalling pathways [22,23]. The elevated
levels of ROS can cause redox imbalance, enhance lipid peroxidation products and induce opening
of the permeability transition pores of the mitochondria. Due to the imbalance of key electrons
in the mitochondria, factors such as pro-caspase, apoptosis initiating factor and cytochrome c are
activated [23–25]. These factors contribute to further damage of the cell by promoting apoptotic cell
death [26–28].
There is also accumulating evidence that oxidative stress caused by increased production of ROS
following hypoxia contributes to the death of dopamine-containing neurons (DCNs) via apoptosis,
leading to the development of Parkinson’s disease (PD), a progressive neurodegenerative disorder [29–31].
Patients diagnosed with PD lack DCNs in the pars compacta region of the substantia nigra (SNpc) and in
the striatum.
The 6-hydroxydopamine (6OHDA) is a well-known neurotoxin which induces neurotoxicity onto
the nigrostriatal dopaminergic system by inhibiting the mitochondrial electron chain complexes I
and IV, and promoting degeneration of DCNs [31–34]. Consequently, it leads to dopamine deficiency
and has a profound impact on dopaminergic receptors. Interestingly, the neurotransmitter dopamine
and its receptors have been shown to be involved in the regulation of breathing [35–37]. Hence,
such degeneration may enhance breathing shortness induced by the aforementioned hypoxic condition,
and further promote pulmonary impairment [29,36]. Moreover, 6OHDA has been reported to be
produced endogenously in PD patients. Thus, in vitro and in vivo models of 6OHDA have been used
to mimic the key attributes such as α-synuclein aggregation, iron accumulation and mitochondrial
dysfunction to study the advanced stages of PD pathogenesis [38–40].
Although intensive research has been conducted, the actual cause of the development and
progression of PD is not yet known. Several lines of evidence suggest that DCNs’ death could be a
result of elevated levels of ROS [39–41], respiratory failure of the mitochondria [42–44], and activation
of NFκB and caspase pathways [44–46]. The role of NFκB in the cell is controversial. A significant
increase in NFκB activity has been reported in the SNpc region of the 1-methyl, 4-phenyl, 1, 2, 3,
6-tetrahydropyridine (MPTP)-treated mice [47]. The authors of [47] suggested that degeneration
of DCNs could have been prevented by selectively suppressing activation of NFκB. In contrast,
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activation of NFκB by Parkin through phosphorylation of IκB triggers transcription of pro-survival
genes. However, NFκB activation by mutant Parkin promotes cell death [48]. Furthermore, activation
of NFκB by 6OHDA in SH-SY5Y neuroblastoma cells has been shown to initiate caspase-3 activation
and, as a consequence, death of DCNs through the NFκB pathway [49].
Caspases, a family of cysteine proteases (caspase 1–14), exist in most cells in a dormant state
known as zymogens and can be activated through intrinsic or extrinsic routes such as mitochondrial,
NFκB and ER stress pathways [50–52]. Caspases have been classified as either initiator caspases
(e.g., caspase-2, -8, -9 and -10) or effector caspases (e.g., caspase-3, -6 and -7) as upstream and
downstream, respectively [53,54]. Initiator caspases such as caspase -2 and -8 are activated via the
dimerization process instead of cleavage and can activate effector caspases, resulting in the death of
cells via apoptotic routes [53,54].
The development and progression of SARS-CoV-2 and PD are a pool of undefined complex cellular
and molecular events. The cell death mechanisms involved in these events are not fully understood.
Since oxidative stress is one of the causes of respiratory hypoxia seen in SARS-CoV-2 and PD patients,
we aimed to investigate similarities in apoptotic pathways which are activated in response to oxidative
stress and their correlation with NFκB activation in both diseases. Understanding the links between
oxidative stress, the consequent activation of NFκB and the resulting cellular and molecular responses
of downstream genes requires a systematic understanding of the pathways that lead the cells to
injuries or apoptotic death. The present study utilizes experimental data, bioinformatics analyses
obtained from Basic Local Alignment Search Tool of protein databases (BLASTP) search, and a literature
review to investigate NF-κB and caspase activation under SARS-CoV-2-mediated infection and in
6OHDA-treated differentiated DCNs (dDCNs) from an immortalized human neural progenitor cell
line derived from the ventral mesencephalon region of the brain (ReNVM) [55,56].
2. Materials and Methods
2.1. Bioinformatics Analysis: SARS-CoV-2 Infection
Upon cell entry, SARS-CoV-2 releases its RNA genome containing around 14 open reading frames
(ORFs), which encode structural or non-structural proteins that contribute to the virus survival and
virulence [57]. In this analysis, the sequences of these SARS-CoV-2 ORF-encoded proteins were
obtained using the NCBI databases and were then compared with the whole human proteome, using
BLASTP search, to look for similarities and to possibly gain further understanding of the function of
these viral proteins.
2.2. Laboratory-Based Analyses: Antibodies and Inhibitors
2.2.1. Primary Antibodies
Anti-NFκB, p65 subunit (MAB3026), anti-tyrosine hydroxylase (TH) and cleaved anti-caspase-3
(AB3623) were purchased from Millipore, Hertfordshire, UK; anti-caspase-2 (ab7979) and anti-caspase-8
(ab52183) were purchased from Abcam, Cambridge, UK.
2.2.2. Secondary Antibodies
Donkey anti-mouse immunoglobulin G (IgG)-horseradish peroxidase (HRP) goat anti-rabbit
IgG-HRP, sheep anti-rabbit IgG-fluorescein isothiocyanate (FITC), sheep-anti-mouse IgG-rhodamine,
goat anti-rabbit IgG-rhodamine and donkey anti-mouse IgG-FITC were purchased from Millipore,
Hertfordshire, UK.
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2.2.3. Inhibitors
Inhibitor of NFκB kinase (IKK; 401479), caspase-2 inhibitor zVDVADfmk (218744), and caspase-8
inhibitor zIETDfmk (218759) were obtained from Merck Chemicals, Nottingham, UK, while universal
caspase inhibitor zVADfmk (G7231) was obtained from Promega, Southampton, UK.
2.3. Cell Culture
ReNVM cells (Millipore, Watford, UK) were cultured either on laminin-coated T25 tissue culture
flasks or chamber slides for Western blot (WB) and immunofluorescence (IF) analyses, respectively.
The cells were maintained in ReNVM neural stem cell maintenance medium (SCM005; Millipore,
Watford, UK) and were differentiated into dopamine-containing neurons (dDCNs) after withdrawal
of epidermal growth factors (EGF) and basic fibroblast growth factor (bFGF). The dopamine marker
tyrosine hydroxylase was used to ensure that ReNVM had differentiated into DCNs (dDCNs). To induce
stress in all relevant experiments, the dDCNs were treated with 100 µm 6OHDA for 2 h, after which
media was replaced with fresh media, and dDCNs were left in the incubator to recover at 37 ◦C overnight
and collected after 24 h as described previously [56]; these cells were termed as 6OHDA-treated dDCNs.
The untreated group was subjected to media change only, termed as control.
For further analysis, caspases-2 and -8 inhibitors zVDVADfmk and zIETDfmk, respectively, were
used after 6OHDA-induced stress to determine if these inhibitors could protect dDCNs following
6OHDA-mediated toxicity. In addition, NFκB inhibitor, IKK and universal caspase inhibitor zVADfmk
were used to determine the involvement of caspases-2 and -8 in the NFκB classical pathway in
control and 6OHDA-treated dDCNs. An optimal condition for the IKK treatment (70 µm for 2 h
exposure) on dDCNs was determined by treating dDCNs with or without 100 µm 6OHDA for 2 h
followed by IKK. To investigate the synergistic effect of IKK with other caspase inhibitors, control
and 6OHDA-treated dDCNs were treated with either caspase inhibitors including caspase-2 inhibitor
(20 µm zVDVADfmk), caspase-8 inhibitor (80 µm zIETDfmk) and universal caspase inhibitor (50 µm
zVADfmk) along with, or without, 70 µm IKK for 2 h. The exposure time of 2 h was kept in coordination
with 6OHDA treatment.
2.4. Immunocytochemistry
Immunocytochemical analysis was used to establish the presence of cleaved p65-NFκB in TH
positive dDCNs following 6OHDA treatment. dDCNs were grown and exposed to 100 µm 6OHDA
for 2 h as described above. On the next day, control and 6OHDA-treated dDCNs were fixed with 4%
paraformaldehyde for 15 min and were washed with cold PBS. Subsequently, cells were treated with
0.1% Triton X-100 (10 min) and blocked with 10% goat serum for 40 min prior to incubation with the
primary antibody (anti-TH, 1:1500,) and with cleaved (p65 subunit) anti-NFκB (1:1500) overnight at
4oC, and incubated with the secondary antibody (sheep anti-rabbit IgG-FITC, 1:800) (sheep-anti-mouse
IgG rhodamine, 1:300) for 2 h at room temperature. dDCNs were mounted using Vectashield mounting
medium and viewed under a Meiji fluorescent microscope (Mazurek, Warwickshire, UK). Furthermore,
co-localisation studies were performed to determine if NFκB and TH (see Figure 1), and NFκB and
caspases (see Figure 2) were present in the same cell by using the primary antibodies anti-TH (1:1500),
anti-NFκB, p65 subunit (1:1500), anti-caspase-3 (1:1000), anti-caspase-2 (1:2000) and anti-caspase-8
(1:2000), and the secondary antibodies donkey anti-mouse IgG-FITC (1:500) and goat anti-rabbit
IgG-rhodamine (1:2500). Control and treated dDCNs were counted under × 20 magnification in 5 fields
of vision per area (1.428 mm × 1.092 mm). To analyse co-localisation data, cells localised in the same
field and stained with two different fluorochromes were counted. Cell numbers are expressed as the
mean per selected field from the wells. Three independent experiments were performed for each
sample prior to statistical analysis (Student’s t-test, p < 0.05), as shown in Figures 1B and 2B.
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is shown to precisely cover the ADP-ribose-binding module in position 238–337 of Nsp3, part of the 
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region of PARP9 that corresponds to Macrodomain 1 located in position 107–296 of PARP9 (UniProt). 
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3.2. 6OHDA-Induced Toxicity Amplifies Activation of NFκB in dDCNs 
To investigate if 6OHDA-induced stress in dDCNs follows the NFκB pathway, double 
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Results showed the presence of p65-NFκB in control and 6OHDA-treated dDCNs (Figure 1A). The 
presence of p65-NFκB in control dDCNs is not surprising as NFκB is a diverse transcription factor 
required for several cellular functions. However, the control dDCNs showed a lower expression of 
p65-NFκB than that of the TH (Figure 1A, left panel). This could simply reflect a difference in 
sensitivity between TH and NFκB antibodies; although, the exposure of dDCNs to 6OHDA increased 
the number of p65-NFκB positive cells (Figure 1A, right panel), indicating activation of NFκB 
following 6OHDA-induced stress. 
Quantitative analysis (see Section 2.4; Immunocytochemistry for detail) showed a difference in 
the number of p65-NFκB cells expressed in TH-positive 6OHDA-treated and control dDCNs. P65-
NFκB was expressed in 54% of TH-positive control dDCNs. However, 6OHDA-induced stress 
significantly increased (46%) the proportion of p65-NFκB in dDCNs, illustrating that 6OHDA triggers 
activation of NFκB in dDCNs (Figure 1B). Western blot (WB) analysis also revealed a substantial 
increase (122%) in the amount of p65-NFκB in 6OHDA-treated dDCNs compared to control dDCNs 
(Figure 1C,D), supporting the notion that 6OHDA-induced stress triggers NFκB activation. 
 
Figure 1. The effect of 6-hydroxydopamine (6OHDA) treatment on NFκB expression in differentiated 
dopamine-containing neurons (dDCNs). The 6OHDA-treated dDCNs were exposed to 100 µm 
6OHDA for 2 h to induce stress, as mentioned in Section 2.4. (A) Figure shows positive staining for 
TH (green), a marker for dopaminergic neurons, in control and 6OHDA-treated dDCNs, indicating 
that cells are dopamine-containing neurons. Positive staining for the p65-NFκB (red) was found in 
control and 6OHDA-treated dDCNs. The white arrow indicates positive staining for TH and p65-
Figure 1. The effect of 6-hydroxydopamine (6OHDA) treatment on NFκB expression in differentiated
dopamine-containing neurons (dDCNs). The 6OHDA-treated dDCNs were exposed to 100 µm 6OHDA
for 2 h to induce stress, as mentioned in Section 2.4. (A) Figure shows positive staining for TH (green),
a marker for dopaminergic neurons, in control and 6OHDA-treated dDCNs, indicating that cells are
dopamine-containing neurons. Positive staining for the p65-NFκB (red) was found in control and
6OHDA-treated dDCNs. The white arrow indicates positive staining for TH and p65-NFκB in the
same dDCN in both control and 6OHDA-treated dDCNs. Scale bars a and b = 50 µm, while c and
d = 100 µm. (B) The graph illustrates the proportion of the p65-NFκB expressed in TH positive control
and 6OHDA-treated dDCNs. Increased expression of the p65-NFκB was observed in dDCNs following
exposure to 6OHDA, indicating that 6OHDA-induced toxicity enhanced NFκB activity in dDCNs.
Means of three experiments ± SEM are shown, p < 0.05. (C) The effect of 6OHDA treatment on p65NFκB
level was measured and compared with control and 6OHDA-treated dDCNs. Briefly, cell extracts from
both control and 6OHDA-treated dDCNs were subjected to Western immunoblotting. Membranes
were probed with antibodies for p65NFκB and housekeeping protein GAPDH. (D) Densitometric
analysis showed a significant increase in p65-NFκB level in dDCNs that were treated with 6OHDA.
The (+) and (-) signs indicate with or without treatment respectively. Densitometric value represents
mean ± SEM of five experiments. Table of densitometry values and statistical analysis can be found in
supplementary Table S1 and S2 for B and D, respectively.
2.5. Western Blot Analysis
Control (untreated), 6OHDA-treated, IKK-treated, and 6OHDA + IKK-treated dDCNs were used
for WB analyses. Cells were lysed and protein concentrations were measured using the bicinchonic
acid (BCA) kit (Pierce Biotechnology, Rockford, IL, USA). Fifty micrograms of protein were loaded on
12% gel prior to SDS PAGE, followed by WB. The list of primary and respective secondary antibodies
used in WB analyses is shown in the table below (Table 1):
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Table 1. A list of primary and secondary antibodies used in Western blot analyses.
Primary Antibody Secondary Antibody
anti-NFκB-p65 (1:5000) donkey anti-mouse IgG-HRP (1:6000)
anti-caspase-2 antibody (1:2500) goat anti-rabbit IgG-HRP (1:1000)
anti-caspase-8 antibody (1:1000) goat anti-rabbit IgG-HRP (1:1000)
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Briefly, cell extracts from both control and 6OHDA-treated dDCNs were subjected to Western 
immunoblotting. Membranes were probed with antibodies for p65NFκB and housekeeping protein 
GAPDH. (D) Densitometric analysis showed a significant increase in p65-NFκB level in dDCNs that 
were treated with 6OHDA. The (+) and (-) signs indicate with or without treatment respectively. 
Densitometric value represents mean ± SEM of five experiments. Table of densitometry values and 
statistical analysis can be found in supplementary Table S1 and S2 for B and D, respectively. 
3.3. Increased Expression of Caspases in p65-NFκB Expressed dDCNs Following 6OHDA-Induced Stress 
Here, we sought to explore the involvement of NFκB in caspase pathways triggered by 6OHDA-
induced stress in dDCNs. Co-localisation studies were carried out to determine if specific caspase 
along with p65-NFκB were present in both control and 6OHDA-treated dDCNs. Increased expression 
of p65-NFκB and caspases-2, -3 and -8 were observed in the dDCNs following 6OHDA treatment 
(Figure 2A). Quantitative analysis (see Section 2.4; Immunocytochemistry for details) revealed a 
positive correlation between caspases-2, -3, -8 and p65-NFκB in 6OHDA-treated dDCNs. Statistical 
analysis was performed using ANOVA and Student’s t-test to measure the statistical differences in 
the proportion of p65-NFκB positive cells that express caspase along with p65-NFκB in dDCNs before 
and after exposure to 6OHDA (Figure 2B). Control p65-NFκB-positive dDCNs expressed 45%, 31% 
and 34% caspases-2, -3 and -8, respectively. However, 6OHDA treatment increased the expression of 
caspases-2, -3 and 8 to 88%, 54% and 100%, respectively. These results indicate that caspases-2, -3 
and -8 are involved in NFκB-mediated death in 6OHDA-treated dDCNs, suggesting involvement of 
NFκB pathway(s) in the death of dDCNs. 
 
Figure 2. The effect of 6OHDA treatment on the expression of caspases in NFκB-positive dDCNs. (A) 
Figure shows positive staining for p65-NFκB (green) and for caspase-2, -3 and -8(red) in control and 
6OHDA-treated dDCNs. Caspase-2 expression was observed in the majority of p65-NFκB positive 
control dDCNs. A higher expression of caspase-3 was observed in p65-NFκB positive 6OHDA-treated 
dDCNs when compared to control dDCNs. Caspase-8 was found in low levels in control dDCNs, but 
an increased expression of caspase-8 was observed in p65-NFκB positive 6OHDA-treated dDCNs. 
White arrow indicates the positive staining of some dDCNs stained with the p65-NFκB and caspase-
2 (upper panel), p65-NFκB and caspase-3 (middle panel) and p65-NFκB and caspase-8 (lower panel) 
in both control and 6OHDA-treated dDCNs. Scale bar = 100 µm. (B) Graph shows the proportion of 
Figure 2. The effect of 6 treat ent on the expression of caspases in NFκB-positive dDCNs.
(A) Figure shows positive staining for p65- FκB (green) and for caspase-2, -3 and -8(red) in control and
6OHDA-treated dDCNs. Caspase-2 expression was observed in the majority of p65-NFκB positive
control dDCNs. A higher expression of caspase-3 was observed in p65-NFκB positive 6OHDA-treated
dDCNs when compared to control dDCNs. Caspase-8 was found in low levels in control dDCNs,
but an increased expression of caspase-8 was observed in p65-NFκB positive 6OHDA-treated dDCNs.
White arrow indicates the positive staining of some dDCNs stained with the p65-NFκB and caspase-2
(upper panel), p65-NFκB and caspase-3 (middle panel) and p65-NFκB and caspase-8 (lower panel) in
both control and 6OHDA-treated dDCNs. Scale bar = 100 µm. (B) Graph shows the proportion of the
p65-NFκB positive cells that expressed caspases-2, -3 and -8 in control and 6OHDA-treated dDCNs.
The proportion of caspases-2, -3 and -8 was expressed in less than half of p65-NFκB positive control
dDCNs. A significant increased proportion of caspases-2, -3 and -8 in p65-NFκB positive cells was
observed after 6OHDA treatment. The (+) and (-) signs indicate with or without treatment respectively.
Means of three experiments ± SEM are shown. A table of values and statistical analysis can be found in
supplementary Table S3.
2.6. MTT Assay
The 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT, Cambridge Bioscience,
UK) assay was performed to measure survival of dDCNs following different treatments in control
and 6OHDA-treated dDCNs. Briefly, dDCNs were grown in 96 well plates and were left until 80%
confluence. dDCNs were treated with different combinations of inhibitors (see Figures for details)
along with 6OHDA for 2 h, after which old media was replaced with fresh media and cells were left to
recover overnight as described above. The following day, old media was replaced with fresh media
prior to the addition of 10 µL of MTT per well. All samples were left to incubate at 37 ◦C for 4 h.
The formazan complex was broken by pipetting the crystals up and down in each well. Subsequently,
samples were placed in a microplate reader and the programme Stingray was used to determine the
readings of samples at 570 nm wavelength. The readings were normalised prior to statistical analysis
at p < 0.05 using ANOVA and Student’s t-test. Three independent experiments were conducted each
for untreated, 6OHDA-treated and inhibitor(s)-treated dDCNs.
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2.7. TUNEL Assay
To explore if 6OHDA stimulates death of dDCNs via apoptotic or necrotic pathways, the terminal
deoxynucleotidyltransferase (TdT)-mediated 2′-deoxyuridine 5′-triphosphate nick end-labelling assay
(TUNEL) in control and 6OHDA-treated dDCNs was performed as recommended by the manufacturer
(Trevigen, MD, USA). Various inhibitors, such as IKK, zVADfmk, zVDVADfmk and zIETDfmk, in the
presence and/or absence of 6OHDA, were also used. The proportion of apoptotic dDCNs was
determined by TUNEL absorbance at 450 nm.
2.8. Detection and Statistical Analysis
Band analysis was carried out using a densitometer (GS800, Bio-Rad, Hertfordshire, UK).
Blots were scanned using GS800 scanner, the band lanes and bands were detected automatically using
Quantity One software at default settings, and the raw densitometric intensity values were obtained.
The housekeeping protein Gylceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used as a
reference guide and the densitometric values for the experimental samples were normalised against
GAPDH to determine the densitometric ratio prior to carrying out statistical analysis (Student’s t-test,
p < 0.05, ANOVA, p < 0.05). All results in graphs are shown as relative percentage compared with
control to provide better comparison between control and 6OHDA-treated dDCNs.
Three to five independent experiments were performed for each treatment and values are indicated
in ± SEM. Table of values and statistical analysis can be found in supplementary data; the relevant
number of experiments performed is mentioned in the figure legends.
3. Results
3.1. SARS-CoV-2 Infection Induces Pro-Apoptotic Responses
Significant matches obtained from BLASTP search involved the viral polyprotein pp1ab,
which resembled two human proteins PARP14 and PARP9, as shown in Table 2. Viral pp1ab
originates from the genome regions that encode non-structural proteins (Nsps), ORF1a and ORF1b,
which are translated into two overlapping polyproteins, pp1a and pp1ab, via a ribosomal shifting
event. These polyproteins are further cleaved through encoded proteases into 1–11 Nsps (pp1a) and
1-16 Nsps (pp1ab) [57]. Results demonstrate that pp1ab shares 32% identities and 49% positives with
human protein mono-ADP-ribosyl transferase PARP14 (E-value: 3 × 10−6) at the 1056–1169 position of
pp1ab, whereas at the 1057–1186 position pp1ab shares 31% identities and 45% positives with human
protein mono-ADP-ribosyl transferase PARP9 (E-value: 2 × 10−4) (Table 2).
The positions of SARS-CoV-2 pp1ab, that resemble human PARP isoforms, encompass the Nsp3
viral non-structural protein region. This is a large multifunctional protein comprising various domains,
which are differently organised across CoV genera. Interestingly, this region of similarity is shown to
precisely cover the ADP-ribose-binding module in position 238–337 of Nsp3, part of the conserved Nsp3
macrodomain X, which is known to remove mono-ADP-ribose from many targets [12,57]. The similarity
observed between viral Nsp3 and human PARP9 specifically encompasses a region of PARP9 that
corresponds to Macrodomain 1 located in position 107–296 of PARP9 (UniProt). These results suggest
important information about the function of the viral Nsp3, when considering its resemblance with
PARP human isoforms, as discussed later.
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Table 2. Basic Local Alignment Search Tool of Protein Databases BLASTP search results of SARS-CoV-2
pp1ab similarity with human protein mono-adenosine diphospate (ADP)-ribosyl transferase 14,PARP14
(Alternative name: Poly [ADP-ribose] polymerase 14) (2a) and with human protein mono-adenosine
diphosphate (ADP)-ribosyl transferase 9,PARP9 (Alternative name: Poly [ADP-ribose] polymerase 9)
(2b). Query refers to the protein sequence of pp1ab and sbjct refers to the protein sequence of PARP9 or
PARP14 correspondingly.
2a. Protein mono-ADP-ribosyl transferase PARP14 isoform x2 [Homo sapiens]
Sequence ID: Length: Number of Matches:
XP_0011511231.1 1209 1
Score: Expect: Method: Identities: Positives: Gaps:
56.6 bits(135) 0.000003 Compositional matrix adjust. 40/124(32%) 61/124(49%) 14/124(11%)
Query 1056 VVVNAANVYLKHGGGVAGALNKATNNAMQV ES DDYIATN GP LKV GGS CVLSGHNLA- KHC 1114
VVVNA+ N LKH GG+A AL+ KA + Q + D + G L G + + L H
Sbjct 818 VVVNAS NED LKHY GGLAAALS KAAGP E LQADCDQIVKRE GR LLP GNAT I SKAGKLP YHHV 877
Query 1115 LHVVGPNVNKGED - - - IQLLK SAYE - - - - - - NFNQHEVLLAPLL SAG I FGADPIHSLRVC 1165
+H VGP + E + LL+ A + + + + P + S +G+FG L C
Sbjct 878 I HAVGPRWSG Y EAPRCVYLLRRAVQLSLCLAEKYKYR S I AIPAI S S GVFG - - - - FPLGRC 933
Query 1166 VDTV 1169
V+T +
Sbjct 934 VET I 937
2b. Protein mono-ADP-ribosyl transferase PARP9 isoform a [Homo sapiens]
Sequence ID: Length: Number of Matches:
NP_001139574.1 854 1
Score: Expect: Method: Identities: Positives: Gaps:
50.4 bits(119) 0.0002 Compositional matrix adjust. 44/142(31%) 65/142(45%) 16/142 (11%)
Query 1057 VVNAANVYLKHGGGV AGALNKATNNAM QVESDD YI ATNGPLKVGGSCVLSGHNLA- KHCL 1115
VVNAAN L HGGG+ A AL KA + Q ES ++A G + G V L K +
Sbjct 135 VVNAANEDLL HGGGLAL ALV KAGGF E I Q E ESKQ FVARYGKVSAGEIA VTGAGRLP CKQ I I 194
Query 1116 HVVGPNVN KGE - - - - - - D I QLLKSAYENF - - - - NQ H-EV LLAPLLSAGIFGADPIHSLRV 1164
H VGP + + + Q + N+ N H + + P LS +GIF L +
Sbjct 195 HAVGPRWMEWDKQGCTGKLQRAIVS IL NY VIYKNT HIKTVAI PALSSGIFQ - - - - FP LNL 250
Query 1165 CVDTVRTNVYL A VFDKNLYDK L 1186
C T + + + + + K + L
Sbjct 251 CTK T I VET I RV S LQGKPMMSNL 272
3.2. 6OHDA-Induced Toxicity Amplifies Activation of NFκB in dDCNs
To investigate if 6OHDA-induced stress in dDCNs follows the NFκB pathway,
double immunocytochemistry (ICC) analysis using NFκB and tyrosine hydroxylase (TH) was performed.
Results showed the presence of p65-NFκB in control and 6OHDA-treated dDCNs (Figure 1A).
The presence of p65-NFκB in control dDCNs is not surprising as NFκB is a diverse transcription factor
required for several cellular functions. However, the control dDCNs showed a lower expression
of p65-NFκB than that of the TH (Figure 1A, left panel). This could simply reflect a difference in
sensitivity between TH and NFκB antibodies; although, the exposure of dDCNs to 6OHDA increased
the number of p65-NFκB positive cells (Figure 1A, right panel), indicating activation of NFκB following
6OHDA-induced stress.
Quantitative analysis (see Section 2.4; Immunocytochemistry for detail) showed a difference in the
number of p65-NFκB cells expressed in TH-positive 6OHDA-treated and control dDCNs. P65-NFκB
was expressed in 54% of TH-positive control dDCNs. However, 6OHDA-induced stress significantly
increased (46%) the proportion of p65-NFκB in dDCNs, illustrating that 6OHDA triggers activation of
NFκB in dDCNs (Figure 1B). Western blot (WB) analysis also revealed a substantial increase (122%)
in the amount of p65-NFκB in 6OHDA-treated dDCNs compared to control dDCNs (Figure 1C,D),
supporting the notion that 6OHDA-induced stress triggers NFκB activation.
3.3. Increased Expression of Caspases in p65-NFκB Expressed dDCNs Following 6OHDA-Induced Stress
Here, we sought to explore the involvement of NFκB in caspase pathways triggered by
6OHDA-induced stress in dDCNs. Co-localisation studies were carried out to determine if specific
caspase along with p65-NFκB were present in both control and 6OHDA-treated dDCNs. Increased
expression of p65-NFκB and caspases-2, -3 and -8 were observed in the dDCNs following 6OHDA
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treatment (Figure 2A). Quantitative analysis (see Section 2.4; Immunocytochemistry for details) revealed
a positive correlation between caspases-2, -3, -8 and p65-NFκB in 6OHDA-treated dDCNs. Statistical
analysis was performed using ANOVA and Student’s t-test to measure the statistical differences in the
proportion of p65-NFκB positive cells that express caspase along with p65-NFκB in dDCNs before
and after exposure to 6OHDA (Figure 2B). Control p65-NFκB-positive dDCNs expressed 45%, 31%
and 34% caspases-2, -3 and -8, respectively. However, 6OHDA treatment increased the expression of
caspases-2, -3 and -8 to 88%, 54% and 100%, respectively. These results indicate that caspases-2, -3 and
-8 are involved in NFκB-mediated death in 6OHDA-treated dDCNs, suggesting involvement of NFκB
pathway(s) in the death of dDCNs.
3.4. IKK Suppressed Activation of p65-NFκB in 6OHDA-Treated dDCNs
The classical, alternative and atypical pathways stimulate NFκB activation. To determine if
6OHDA-induced stress triggered the NFκB classical pathway in dDCNs, an IKK-inhibitor 401479,
which specifically suppresses the NFκB classical pathway, was used. IKK inhibited activation of
p65-NFκB in 6OHDA-treated dDCNs, demonstrating that 6OHDA-induced stress stimulates the NFκB
classical pathway. WB analysis showed 44% increased expression of p65-NFκB in 6OHDA-treated
dDCNs. However, the absence of NFκB in 6OHDA + IKK-treated dDCNs compared with control
signified the involvement of the NFκB classical pathway in the death of dDCNs (Figure 3A,B).
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Figure 3. 6OHDA stimulates the classical NFκB pathway in dDCNs. (A) Control and 6OHDA-treated
dDCNs were treated with 70 µM Inhibitor of NFκB kinase (IKK for 2 h (see Section 2.3).
Cell extracts were subjected to WB immunoblotting and membranes were probed with p65-NFκB
and Gylceraldehyde-3-Phosphate Dehydrogenase (GAPDH) antibodies. The absence of NFκB was
observed in IKK-treated dDCNs, suggesting that the NFκB classical pathway is involved in death of
dDCNs. Illustrative examples of p65-NFκB and housekeeping protein GAPDH in control, IKK, 6OHDA,
IKK + 6OHDA-treated dDCNs are shown. (B) Densitometric analysis showed a significant increase in
p65-NFκB levels in 6OHDA-treated dDCNs compared to control dDCNs (p < 0.01). (C) Control and
6OHDA-treated dDCNs were treated with zVADfmk and IKK. Results showed that combined treatments
significantly decreased death of 6OHDA-treated dDCNs. However, both inhibitors synergistically could
not provide complete inhibition of cell death induced by 6OHDA toxicity in dDCNs. The proportion of
cells surviving was determined by MTT absorbance at 570 nm. The (+) and (-) signs indicate with or
without treatment respectively. Means of three experiments ± SEM are shown in B and C. A table of
densitometry values and statistical analysis can be found in supplementary Tables S4 and S5 for B and
C, respectively.
To find if 6OHDA-induce stress can trigger a ditional pathways ot er than the NFκB classical
pathway that results in death of dDCNs, a combined effect of universal caspase inhibitor zVADfmk
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and a specific NFκB inhibitor IKK was used. zVADfmk and IKK significantly increased the survival of
6OHDA-treated dDCNs (50% and 54%, respectively) compared to 29% in 6OHDA-treated dDCNs.
A further increase in cell survival was found when 6OHDA-treated dDCNs were treated with zVADfmk
along with IKK (73%), showing the synergistic effect of both inhibitors. However, both inhibitors were
unable to provide 100% protection to 6OHDA-treated dDCNs, indicating that other caspase-related
pathway(s) might be contributing towards the death in 6OHDA-treated dDCNs (Figure 3C).
3.5. OHDA Provokes Apoptotic Death in dDCNs
The subsequent aim was to determine if 6OHDA-induced stress in dDCNs follows necrotic or
apoptotic pathways. To achieve this, the Tunnel assay was performed. The results showed that 6OHDA
treatment significantly encouraged death of dDCNs through an apoptotic pathway. ANOVA and
Student’s t-test analysis (p < 0.05) revealed a significant difference in the level of apoptotic death in
6OHDA-treated dDCNs (272%). Apoptotic death of dDCNs confirms that 6OHDA-induced oxidative
stress triggers caspase activation, resulting in the death of dDCNs via the apoptotic route (Figure 4).
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ribosylation process [58]. STAT1 is particularly important in the IFN receptor signalling pathway 
where it forms homo or heterodimers, following its phosphorylation at tyrosine position 701 (STAT1 
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Figure 4. 6OHDA triggered apoptotic death in dDCNs. To determine if 6OHDA stimulated death of
dDCN is via the apoptotic or necrotic route, the TUNEL assay was used. Various inhibitors such as
IKK, zVADfmk, zVDVADfmk, and zIETDfmk were used with 6OHDA to determine if the inhibitor
decreased 6OHDA-me iated death of dDCNs. 6OHDA triggered death of dDCNs via the apoptotic
route. The result illustr es that all studied inhibitors reduced apopto ic death of dDCNs at various
rates. The re ult is shown as the relative percentage of cell death compared wi h control. The (+) and
(-) signs indica e with or without treatment respectively. Means of thr e experi e ts are shown.
A table of values and statistical analysi can be found in sup lementary dat S6.
4. Discussion
The results from our bioinformatics analysis show a similarity between SARS-CoV-2 Nsp3 and
human PARP14 (Table 2a). Human PARP14 is a protein involved in the STAT1 mono-ADP-ribosylation
process [58]. STAT1 is particularly important in the IFN receptor signalling pathway where it
forms homo or heterodimers, following its phosphorylation at tyrosine position 701 (STAT1 Tyr701).
This contributes to the formation of downstream factors that translocate to the nucleus and in turn affect
gene expression. Mono-ADP ribosylation of STAT1 by PARP14 impedes STAT1 phosphorylation and, as
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a consequence, downregulates the responses triggered by interferons (IFNs) [58]. Recent evidence [12]
shows matching protein sequence similarity results with correspondence to PARP14 when comparing
SARS-CoV-2 Nsp3 protein against the human proteome using BLASTP, while we compared all
SARS-CoV-2 ORF-encoded proteins against the human proteome using BLASTP, and found the
significant similarities between pp1ab and PARP human isoforms that resulted to encompass
the Nsp3 region of the viral pp1ab. Considering that the SARS CoV-2 Nsp3 macrodomain
shares similarity with PARP14, yet both are known to perform opposing functions with regard
to ADP-ribose removal/addition, it has been suggested that the two possess similar conformation
and compatibility for the removal (Nsp3) and addition of ADP-ribose (PARP14) in STAT1. Thus, in
an IFN-activated cell, expressed viral Nsp3 will counteract mono-ADP-ribosylation of STAT1 and
therefore upregulate STAT1 phosphorylation [12]. Our evidence of pp1ab similarity with PARP9,
although less significant than with PARP14, implies that Nsp3 shares sequence similarity with the
Macrodomain 1 region of PARP9 (Table 2b), which is dispensable for interaction with STAT1 and
suppression of PARP14-mediated STAT1 ADP-ribosylation [58,59]. This further supports the potential
role of Nsp3 in promoting STAT1 phosphorylation in response to IFN-
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stimulation, and therefore
prolonging STAT1-dependent expression of IFN-stimul ted genes. This prolonged expression can
potentially engender the several consequences corresponding with the severity of COVID-19, including
enhanced inflammation/cytokine storm as explained by Clevery [12]. Further to this, we investigated
the role of promoted STAT1 phosphorylation in enhanced pro-apoptotic responses. The latter is
harmonious with the literature findings demonstrating that prolonged activated STAT1 tips the cell
survival balance toward IFN-
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caspase-3 t  promote cell destruction [44,63]. 
Al hough we have not studied the STAT1 phosphorylation pr cess in our experime tal PD 
model, there is  wealth f information sh wing the activa on f STAT1 following hypoxia, leading 
t  inflamm tory r ponse activat d by IFN-ϒ, gangliosides and NFκB [64–67]. Oxidative stress 
caused by respiratory hypoxia also ctivates NFκB and has a negative impact on the function of DJ-
1 (Parkinson protei  7-PARK7). Mutatio s of the latter have b en identified in early onset autosomal 
recessive PD. Several investigations su gest that loss of PARK7 function may in rease the PD risk 
thr ugh enhanced brain inflammation. Cons dering that DJ-1 normally functions to prevent 
rolonged STAT1 ctivation, loss of it  functio  is shown to lea  to increased STAT1 phosphorylation 
and upregulated inflammatory me iato s in response to I -ϒ,γ similar to SARS-CoV-2 infection 
[65]. Likewise, increased STAT1 phosphorylation will potentially result in caspase-2 and -8 
activation, as well as NFκB activation [9–11,60,62]. A mass destruction of DCNs caused by prolonged 
inducible interferon
regulatory factor 1 (IRF1) enhanced tr nscription, or by STAT1 independently. Hence, increased STAT1
phosphorylation in the presenc of viral Nsp3 protei may lead to incre ed caspase-8 expression, thus
promoting apoptosis initiation by the cleavage of the downstream effector caspases [60]. Investigations
have also shown that STAT1 is important in regulating the constitutive mRNA level of caspase-2 and
thus promoting apoptosis [62]. Another recent study further supports the involvement of caspase-8 in
SARS-CoV-2 induced apoptosis [63] implying that ORF3a, a cell membrane-associated viral protein,
induces the cleavage/activation of caspase-8, which then acts to convert B-cell lymphoma 2 homology
domain 3 interacting-domain (BID) to truncated p15 BID (tBID) [63]. Subsequently, tBID binds to the
pores of the mitochondria, thereby promoting the opening of mitochondrial PTP triggering cytochrome
c release, followed by apoptosome formation and caspase-9 activation, which in turn activates effector
caspase-3 to promote cell destruction [44,63].
Although we have not studied the STAT1 phosphorylation process in our experimental PD
model, there is a wealth of information showing the activation of STAT1 following hypoxia, leading to
inflammatory response activated by IFN-
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The results from our bioinformatics analysi  show a si il r ty betwe  SARS-CoV-2 Nsp3  
human PARP14 (Table 2 ). Human P RP14 is a protein involved in the STAT1 mono-ADP-
ribosylation process [58]. STAT  is pa icul rly mportant n the IFN r ceptor signalli g pathway 
where it forms h mo or heterodi ers, following its phosphorylat o  at tyrosine pos ion 701 (STAT1 
Tyr701). This contributes to the f rmation of do nstream f t rs that translocate to the nucleus and 
in turn affect gene expression. Mo o-ADP ribosylat of STAT1 by PARP14 impe es STAT1
phosphorylation and, as a consequence, downregulate  the re onses triggered by nterf rons (IFNs) 
[58]. Recent evidence [12] shows matc ng protein sequenc  similar ty results with cor spondence 
to PARP14 when comparing SARS-CoV-2 Nsp3 prot in against the huma  proteome using BLASTP, 
while we compared all SARS-C V-2 ORF-encoded proteins against the huma  proteome using 
BLASTP, and found t  significant simi rities between pp1ab an  PARP human is forms that 
resulted to encompass the Nsp3 region f h  vi l pp1 b Considering that th  SARS CoV-2 Nsp3 
macrodomain shares similarity with PARP14, yet both are known to perform opposing functions 
with regard to ADP-ribose removal/additi n, t has b en sugg ted th t the two possess imil  
conformation and compatibility for th  emoval (Nsp3) an  addit on of ADP- ibose (PARP14) in 
STAT1. Thus, in an IFN-activated cell, expressed vi al Nsp3 will counteract mono-ADP-ribosylation 
of STAT1 and ther ore upregulate STAT1 phospho ylatio  [12]. Our vidence of pp1ab sim larity 
with PARP9, although less signif cant han with PARP14, implies that Nsp3 hares sequence
similarity with the Macrodomain 1 region of PARP9 (Tabl  1b), which is dispensable for interac on 
with STAT1 and suppression of PARP14-mediated STAT1 ADP- ib sylatio  [58,59]. This further 
supports the potential role of Nsp3 in p omo ing STAT1 phosph rylation in r sponse to IFN-ϒ 
stimulation, and herefore prolong ng STAT1-dependent expression of IF -stimulated gen s. This 
prolonged expression ca  pot n ally eng nder e several consequ nces cor sponding with he 
sev rity of COVID-19, includi g enh ced inflammat on/cytokine st rm as explained by Clevery 
[12]. Fur her to this, we i vestigated the role f promoted STAT1 hos horylation in e nced pro-
apoptotic resp nses. The latter is harmonious th the literature finding  mons r ing that 
prolong d activated STAT1 tips the cell survival b lance toward IFN-ϒ-i duced apoptosis. This is 
sh wn to be m dia ed by the upreg lation of caspase-8 in particular [60,61], and partially caspa e -
2,-3 and -7 [62]. Reg rding caspase-8, th r  is evidence nd cating tha  its pregulatio  i  sign lled 
through STAT1 and IFN ϒ nducible interferon regulato y factor 1 (IRF1) enhanced tran crip ion, or 
by TAT1 i d pendently. Hence, increa ed ST T1 phosph rylation i  the presence of viral Nsp3 
protein may lead to increased caspas -8 expression, thus promoti g apopt is initia ion by the 
cleavage of the downstrea  effector caspases [60]. Investigations have lso s own that STAT1 is 
important in regulating the c nstitutiv  mRNA level of caspase-2 and thus promoting apoptosis [62]. 
Another rec nt study further supports the inv lveme t of c spase-8 in SARS-CoV-2 i duc d 
poptosi [63] implying that ORF3 , a cell membra e-associated viral r tei , induces the 
cleavage/activation of caspase-8, which then acts to convert B-cell lymphoma 2 mology domain 3 
interacting-domain (BID) to truncated p15 BID (tBID) [63]. Subsequently, tBID binds t  the pores of 
the mitochondria, thereby promoting the opening of mito hondrial PTP triggering cytochrome c 
release, followed by apoptosome formation and caspase-9 activation, which in turn activa es effector 
caspase-3 to promote cell destructio  [44,63]. 
Although we have not studied the STAT1 phosphorylation process in our experimental PD 
model, there is a wealth of information showing the activation of STAT1 following hyp xia, leading 
to inflammatory response ctivated by IFN-ϒ, gangliosides a d NFκB [64–67]. Oxidative stress 
caused by respiratory hypoxia also activates NFκB and has a negative impact on the function of DJ-
1 (Parkinson protein 7-PARK7). Mutations of the latter have been ide tified in arly onset autosomal 
recessive PD. Several investigations suggest that loss of PARK7 function may increase the PD risk 
through enhanced brain inflammation. Considering that DJ-1 normally functions to pr vent 
prolonged STAT1 activation, loss of its function is shown to lead to increased STAT1 phosphorylati n 
and upregulated inflamm tory mediators in response to I -ϒ,γ similar to SARS-CoV-2 infection 
[65]. Likewise, increased STAT1 phosphorylation will potentially result in caspase-2 and -8 
activation, as well as NFκB activation [9–11,60,62]. A mass destruction of DCNs caused by prolonged 
, gangliosides and NFκB [64–67]. Oxidative stress caused by
r spiratory hyp xia also ctivates NFκB a d has a negative impact on the function of DJ-1 (Parkinson
protein 7-PARK7). Mutations of the latter have been identified in early onset autosomal recessive
PD. Several investigations suggest that loss of PARK7 function may increase the PD risk through
enhanced brain inflammation. Considering that DJ-1 normally functions to prevent prolonged STAT1
activation, loss of its function is shown to lead to increased STAT1 phosphorylation and upregulated
inflammatory mediators in response to IFN-
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The results from our bioi formatics nalysis show a simila ty between SARS-CoV-2 sp3 and 
human PARP14 (T ble 2a). Hu n PARP14 is a protein i volved in the STAT1 mono-ADP-
ribosylation process [58]. TAT1 is particularly important i  the IFN r cepto signalling pathway 
here it fo ms homo or heterodi s, following its phosphorylatio  at tyrosi e position 701 (STAT1 
Tyr701). This contributes to the formation f downstr am factors th t ranslocate to th  nucleus and 
n tur  affect gen ex ression. Mono-ADP ribosylation of STAT1 by P P14 impedes STAT1 
phosphorylation and, as a consequence, downre lates the responses t ggered by interfer  (IFNs) 
[58]. Recent evidenc [12] show  m ching ro e n sequ c s mil rity results with corres on ence
to PARP14 wh n c mparing S RS-CoV-2 Nsp3 protein ain t th  human pr t m usi g BLASTP, 
while w comp red all SARS-C V-2 ORF-encoded proteins ag inst th human pr teom using 
BLASTP, and found the ignificant similarities between pp1ab and PARP hu an isofo ms that 
resulted to e compass the Nsp3 reg o  of  viral pp1ab. Cons deri g that th  SARS CoV-2 Nsp3
macrodomain hares similar ty wi h PARP14, yet bo h re known to perform opposing functions 
with regard to ADP-rib se removal/addition, it has been sugg s ed that the two ossess similar 
con ormatio  nd compatibility f  th  mova  (Ns 3) and additi n of ADP-ribose (PARP14) in 
STAT1. Thus, in  IFN-activated cell, exp s d vira  Nsp3 will counter ct mon -ADP-ribosylat on 
of STAT1 and therefore upr gulate STAT1 phosph rylation [12]. O r evidence of pp1ab similarit  
with PARP9, al ough less sig ificant han with PARP14, mplie hat Nsp3 shar s sequ nc
similarity with he Macrodoma n 1 r gion f PARP9 (T ble 1b), which is dis e sable for int ra tion 
with STAT1 and suppr ssi n of PARP14-media ed STAT1 ADP- ibosylatio  [58,59]. This fu ther
supports the potential role N 3 n prom ting S AT1 phosphorylation in response to IFN-ϒ 
s imulation, and th r fore pro on ing STAT1-depend nt expression of IFN-s mulated genes. Th s 
prolonged xp ession ca  potentially eng der the several con q ences c rresponding with the 
severity of COVID-19, in ludi g e h c d inflamm /cy okine torm a  exp ained by Clevery 
[12]. Furth r to this, w  investig ted the role of pr moted STAT1 p os orylati n i  enhanced pro-
apoptotic respo s s. The latter is harmonious with the literature findings demonstrating that 
prolong d activat d STAT1 tips the c ll survival bal c  tow rd IFN-ϒ-induced apoptosis. This is 
shown to be mediated by the u reg latio  of caspase-8 in partic l r [60,61], an  partially c spases-
2,-3 nd -7 [62]. Regarding caspa e-8, there is vidence ndicating th t its upregulatio  is signalled 
through STAT1 and IFN ϒ induc ble int rferon regulat ry f ctor 1 (IRF1) enhanced tr cription, or 
by STAT1 i dependently. Hence, increas d STAT1 phosphorylati n in t e pres ce of viral Nsp3 
protein may lead t  inc e s aspase-8 xpression, thus promo ing apoptosis initiation by he 
cleavage of  downstream effector caspases [60]. Investi tions have also shown that STAT1 is 
important in regulating the c nsti utive mRNA l vel of c spase-2 nd thus promoting apop sis [62]. 
Anothe  recent st dy further sup orts the inv lvement of caspase-8 in SARS-CoV-2 induced 
ap ptosis [63] implying that ORF3 , a cell membrane-associated viral rotein, induces the 
cleavage/activa ion of caspase-8, which then acts to c v rt B-cell lymphoma 2 homology domain 3 
inter cting-domain (BID) to runcated p15 BID (tBID) [63]. Subsequently,  binds to th  pores of 
the mitochondria, thereby promoti g the opening f mitochondrial PTP triggering cytochrome c 
release, f llowed by apopt some form ti n and c spas -9 activation, which in turn c ivates effector 
caspase-3 to promote c ll destructi n [44,63]. 
Although we have not s udied th  STAT1 p osphorylation process in our experime tal PD 
model, there is a wealth of information showing the activatio  of STAT1 following ypoxia, leading 
to inflammatory response activated by IFN-ϒ, gangliosides and NFκB [64–67]. Oxida ve stress 
caused by respiratory hypoxia al o activates NFκB and has  negative impact on he fu ction of DJ-
1 (Parkinson protein 7-PARK7). Mutations f the latt r have been id tifi d in arly onset autosomal 
recessive PD. Several investigations suggest that loss of PARK7 function may increase th  PD risk 
through enhanc d brain inflamm tion. Considering that DJ-1 normally functions t  prevent 
prolonged STAT1 activation, loss of its function i  shown to lead to increased STAT1 phosphorylation 
and upregulated inflammatory mediators in response t  I -ϒ,γ similar to SARS-CoV-2 infection 
[65]. Likewise, increased STAT1 phosphorylation will potentially result in caspase-2 and -8 
activation, as well as NFκB activation [9–11,60,62]. A mass destruction of DCNs caused by prolonged 
, similar to S RS- o -2 i f ti [65]. Likewise,
i STAT1 phosphorylation will potentially result in caspase-2 and -8 activation, as well as
NFκB activation [9–11,60,62]. A mass de truction f DCNs caused by prolonged caspase-activation
can contribute to the onset of PD [44,68], while the cleavage of BiD and the translocation of its
truncated form, tBid, to the mitochondria in PD brain has also been reported [69]. This similarity
provides a mechanistic link between development of PD and SARS-CoV-2, which can be further
supported by the laboratory results of the present study, showing increased expression of p65-NFκB and
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caspases-2, -3 and -8 in 6OHDA-treated dDCNs, thus stimulating the NFκB pathway and promoting
apoptotic death.
Work by Masumoto et al. [70] had found that NFκB overactivity was encouraged by elevated
levels of the apoptosis-associated speck-like protein containing caspase-recruitment domain (ASC).
Elevated levels of caspase-8 and NFκB p65 were determined in cells treated with ASC, indicating
an overexpression of ASC promoted apoptotic cell death through NFκB and caspase-8 mechanisms.
IKK inhibited NFκB p65 and caspase-8 apoptotic death of DCNs that had been exposed to ASC and
a member of the Apoptosis-activating family-1 (Apaf-1). In addition, Ye et al. [71] and Xiang et
al. [49] have shown 6OHDA triggered phosphorylation of IκBand translocation of p65 to the nucleus
in SH-SY5Y neuroblastoma cells. ICC and WB analysis revealed that 6OHDA triggered caspase-3
activation and death of DCNs through the NFκB classical pathway [49,71]. These findings are in
parallel with the current study showing that 6OHDA triggers activation of the NFκB classical pathway
leading to caspase-mediated apoptotic death of dDCNs. In addition, our results using NFκB, caspases-2
and -8 specific inhibitors demonstrated that NFκB stimulates caspases-2 and -8 expression in dDCNs
treated with 6OHDA (Figure 4).
Research by Lamkanfi et al. [72] showed that caspase-2 can trigger NFκB activation resulting in
caspase-3 activation and leading to the death of cells. Caspase-2 forms a complex with P53-induced
death domain and receptor interacting protein which promotes NFκB stimulation. However, our results
suggest that NFκB promotes expression of caspase-2 in 6OHDA-treated dDCNs (Figure 2). Similarly,
as seen in SARS-CoV-2 infection, where caspase-8 is important in inducing cell apoptosis (Figure 5),
inhibition of caspase-8 activity has been shown to reduce death of cortical neurons [73]. Interestingly,
increased caspase-8 level in post-mortem brain of LRRK-2-associated PD patients has also been
reported [73]. This indicates that mutated LRRK-2 promotes caspase-8 dependent death of striatal
DCNs in the progression of PD. In comparison, our experimental results clearly demonstrate that
NFκB stimulates expression of caspases-2 and-8, leading to apoptotic death in 6OHDA-treated dDCNs
(Figure 2). Ho et al. [73] studied specific PD brain samples that had been associated with a mutated
LRRK-2 gene, and therefore, in their study only the effect of mutated LRRK-2 gene on caspase could
be determined. Our study, on the other hand, focused on specific caspases and their expression after
administration of 6OHDA, and explored the environmental rather than the genetic aspects of the
damage that led to the death of dDCNs.
DeErausquin et al. [74] have shown increased levels of NFκB and calcium along with ROS
production and decreased IkB expression in rat mesencephalic cultures that were exposed to the
glutamate receptor AMPA. ICC analysis portrayed a significant loss of dendrites in DCNs that were
treated with AMPA, indicating that excitotoxicity might have promoted the stimulation of NFκB,
which in turn led to the death of DCNs. Thus, our results are consistent with the previously published
studies demonstrating that increased production of ROS triggers the expression of caspase-3 via the
NFκB route, leading to the death of cells through the apoptotic pathway [14,54,75]. In other words,
the oxidative stress in both conditions, whether induced by 6OHDA-induced toxicity or mediated
by SARS-CoV-2 infection, shares at least one common inflammatory pathway(s) triggering NFκB
activation. It is worth noting that caspases-2 and -8 are activated via STAT1 signalling, independent of
the NFκB pathway [60–62]. However, since in the present study, NFκB stimulation triggered caspases-2
and -8 expressions in 6OHDA-treated dDCNs, it is tempting to assume that NFκB activation may
lead to activation of these caspases in SARS-CoV-2 infection as well, causing apoptotic cell death and
consequently promoting the development of PD and COVID-19 (Figure 5).
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associated ORF3a viral protein in SARS-CoV-2 infected cells, leading to apoptotic cell death through 
the extrinsic pathway, thus promoting the development of PD and COVID-19. (BioRender software 
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NFκB signalling cascade may be a common inflammatory pathway observed in the pathogenesis of 
both PD and COVID-19. Our results suggest that manipulation of this pathway and/or selective 
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cells without impacting other cellular mechanisms, and can open new windows into potential 
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of PD. However, it is likely that the similarities seen between both disorders may add additional 
Figure 5. Illustration describing inflammation and apoptosis mechanisms in SARS-CoV-2 infection,
suggesting similarity with those in Parkinson’s disease under oxidative stress. The SARS-CoV-2
entry in the cell requires interaction with the surface molecules angiotensin converting enzyme 2
(ACE2) and transmembrane serine protease 2 (TMPRSS2), leading to activation of NFκB via pattern
recognition receptors (PRR), which is further amplified by STAT-1, STAT-3 and oxidative stress, similar
to 6OHDA-induced t xicity in treated dDCNs showing increased p65-NFκB expression. This NFκB
imulation induces caspase-2 and -8 express on 6OHDA-treated dDCNs, wh ch are the upregulated
caspases from prolonged STAT-1 activ tion, NFκB and membrane-associated ORF3 viral protein
in SARS-CoV-2 infected cells, leading to apoptotic cell death through the extrinsic pathway, thus
promoting the development of PD and COVID-19. (BioRender software was used to create this fig re).
5. Conclusions
Taken together, our study of the NFκB signalling pathway in the experimental PD model in
comparison with bioinformatics analysis of SARS-CoV-2, supports the notion that activation of the
NFκB signalling cascade may be a common inflammatory pathway observed in the pathogenesis
of both PD and COVID-19. Our results suggest that manipulation of this pathway and/or selective
inhibition of caspase and NFκB activations through different channels may provide better protection
to the affected cells under stressed conditions. As NFκB is involved in a diverse range of processes that
regulate cellular function in healthy cells, a wide-ranging inhibition of its pathways may contribute to
or cause disruptions at the cellular and physiological levels. Further research involving treatments with
pharmacological agents and identification of key proteins involved in these pathways may identify
potential targets to safely suppress NFκB and caspase activations in stressed cells without impacting
other cellular mechanisms, and can open new windows into potential therapeutic approaches to the
treatment of COVID-19 and PD. It is too early at this point to recognise whether SARS-CoV-2 exposure
will have any long term impact on the development or progression of PD. However, it is likely that the
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similarities seen between both disorders may add additional weight to an enhanced risk or progression
of PD following SARS-CoV-2 infection and/or vice versa in the elderly.
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